- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Vitamin preparation. Benfotiamine is a fat soluble derivative of thiamine (vitamin B1). Thiamine is converted to active thiamine pyrophosphate and is included as a coenzyme in the pyruvate decarboxylase, alpha ketoglutarate decarboxylase complexes, which are involved in the oxidative decarboxylation of pyruvic acid and alpha ketoglutaric acid; transketolase is a pentose phosphate shunt enzyme.
Vitamin B1 deficiency, confirmed by clinical and biochemical studies, developing on the background of:
- insufficient and inadequate nutrition (beriberi disease);
- parenteral nutrition for a long time;
- chronic alcoholism (alcoholic cardiomyopathy, Wernicke encephalopathy, Korsakov syndrome);
- increased need for vitamin B1.
Polyneuropathy due to vitamin B1 deficiency. Typical signs of such a deficiency are neurological disorders in the form of neuropathies with sensory impairments (pain, tingling, loss of sensation in the upper and lower extremities).
Excipients: microcrystalline cellulose - 122 mg, Povidone K30 - 8 mg, glycerides of fatty acids - 5 mg, colloidal silicon dioxide - 7 mg, carmellose sodium - 3 mg, talc - 10 mg.
The composition of the shell: shellac - 3 mg, sucrose - 70.875 mg, calcium carbonate - 66.479 mg, talc - 41.314 mg, acacia gum - 10.155 mg, corn starch - 7.34 mg, titanium dioxide - 10.932 mg, colloidal silicon dioxide - 4.404 mg, povidone K30 - 6.21 mg, macrogol 6000 - 1.597 mg, glycerol 85% - 2.262 mg, polysorbate 80 - 0.133 mg, mountain glycolic wax - 0.3 mg.
Benfotiamine is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
|Benfogamma 150||Verwag Pharma||Germany||dragee|
|Benfogamma 150||Verwag Pharma||Germany||pills|
No customer reviews for the moment.
Dosage and Administration
Dibazol taken orally (2 hours before meals or 2 hours after meals) - 20-50 mg 2-3 times a day for 3-4 weeks or shorter courses.
In the treatment of diseases of the nervous system - 5 mg 1 time per day or every other day, the course - 5-10 doses.
Children under the age of 1 year old - 1 mg once a day, 1-3 years old - 2 mg, 4-8 years old - 3 mg, 9-12 years old - 4 mg, over 12 years old - 5 mg.
The course, if necessary, repeat after 3-4 weeks.
The course of treatment is 8-14 days.
When used in high doses:
- feeling hot
- increased sweating
Warns an increase in OPSS due to non-selective beta-blockers.
Strengthens the hypotensive effect of hypotensive and diuretic drugs.
Phentolamine enhances the hypotensive effect of bendazole.
Pregnancy and Lactation
There are no contraindications.
Use Dibazol with care in elderly patients.
Not recommended for long-term treatment of hypertension, especially in elderly patients.
- Brand name: Dibazol
- Active ingredient: Bendazole
- Dosage form: Pills
- Manufacturer: Uralbiopharm
- Country of Origin: Russia
- Supramolecular self-assembly via inter-ligands hydrogen bonds in [Cu(H2O)2(NO3)2(tb)] (tb is thiabendazole)
- Thiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytes
- Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose
- Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro
- Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives
- Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis
- Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes
- Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes
- Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients
- High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine
- Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications
- Benfotiamine is similar to thiamine in correcting endothelial cell defects induced by high glucose
- Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat
- The Defensive Effect of Benfotiamine in Sodium Arsenite-Induced Experimental Vascular Endothelial Dysfunction
- Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy
- LC Simultaneous Determination of Thioctic Acid, Benfotiamine and Cyanocobalamin in Thiotacid Compound Capsules
- Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations
- Benfotiamine relieves inflammatory and neuropathic pain in rats
- Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages
- Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages
- Structure of benfotiamine hemihydrate
- Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-α
- UP-1.013: Effect of Benfotiamine in Expression of Phosphodiesterase 5 and Isoforms in Type 2 Diabetic Rat Kidney
- Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response